Volume-rendered image processed from data acquired using the Philips 256-slice Brilliance iCT scanner at WellStar Kennestone Hospital in Marietta, GA, shows right iliac artery stenosis and multiple calcifications on left iliac artery. Bony landmarks are ghosted in background, the result of a new visualization technique introduced by Philips to assist in planning interventions. The Marietta installation boosts the number of Philips 256-slice CTs to nine. These sites, located at medical facilities around the world, have scanned more than 6000 patients, according to Philips Healthcare. With rotational speeds up to 0.27 seconds and a detector that spans 8 cm, the iCT supports applications in trauma, cardiac, interventional, pediatric, vascular, and bariatrics, as well as general imaging. Slotted anode and dual-support spiral groove bearing built into the scanner's x-ray tube enable 120- kW imaging and focal spot integrity at high rotational speeds. 'Smart' focal spot simultaneously deflects x-ray beam in x- and z-axes to acquire double the data during each rotation. (Provided by Philips)
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.